BioCryst highlights efficacy gains across hereditary angioedema portfolio
BioCryst Pharmaceuticals (NASDAQ:BCRX) reported new clinical trial data and supportive real-world evidence evaluating its hereditary angioedema (HAE) portfolio at the European Academy of Allergy and Clinical Immunology (EAACI) 2026 Annual Meeting in Istanbul, Turkey.
The data presentations spanned new long-term pediatric findings for its commercial drug Orladeyo (berotralstat) alongside a positive subgroup analysis for its late-stage investigational monoclonal antibody, navenibart.
The company shared updated 48-week results from its ongoing APeX-P study, which represents the largest long-term prophylaxis trial conducted in pediatric HAE patients aged 2 to under 12 years.
The analysis showed that once-daily oral administration of Orladeyo sustained lower HAE attack rates over time, with the median adjusted monthly attack rate requiring on-demand treatment dropping from 0.691 at baseline to 0.169 during the treatment window.
The decrease in swelling episodes corresponded with a sharp drop in acute healthcare utilization—including professional care interventions—while maintaining a clean safety profile with no new tolerability signals identified.
In tandem with its commercial product updates, BioCryst delivered a post hoc analysis from the Phase 1b/2 ALPHA-STAR trial evaluating navenibart, a long-acting injectable plasma kallikrein inhibitor acquired through the company's merger with Astria Therapeutics.
The retrospective review evaluated the therapeutic candidate across key patient cohorts partitioned by baseline attack frequencies, body mass index (BMI), and age.
The candidate successfully reduced overall attack rates, minimized moderate-to-severe swelling episodes, and decreased the reliance on acute on-demand rescue medications uniformly across all subgroups, bolstering the scientific rationale for the asset's active Phase 3 registrational trials.
Complementing the controlled trial datasets, multiple real-world evidence abstracts examined the clinical outcomes of adolescent and adult HAE patients utilizing long-term prophylaxis.
The retrospective tracking indicated that patients experienced sustained reductions in disease burden and healthcare facility usage after transitioning to BioCryst's portfolio, including individuals who previously cycled through alternative long-term preventative injection regimens.
Management noted that the combined data points reinforce the commercial competitive positioning of Orladeyo while validating navenibart's potential to establish flexible three- or six-month dosing intervals within the global rare disease market.
